Ackman Tells Allergan Board "Valeant Can Pay Substantially More For Allergan By Virtue Of The Strategic Overlap"

BZ NOTE: Additional Color "...Any Sales Process That Does Not Include Valeant Is By It's Very Nature Likely To Lead To A Sub-optimal Outcome For Shareholders"